These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 33686114)

  • 21. Activation of the Kynurenine Pathway in Human Malignancies Can Be Suppressed by the Cyclin-Dependent Kinase Inhibitor Dinaciclib.
    Riess C; Schneider B; Kehnscherper H; Gesche J; Irmscher N; Shokraie F; Classen CF; Wirthgen E; Domanska G; Zimpfer A; Strüder D; Junghanss C; Maletzki C
    Front Immunol; 2020; 11():55. PubMed ID: 32117235
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pro-survival signal inhibition by CDK inhibitor dinaciclib in Chronic Lymphocytic Leukaemia.
    Chen Y; Germano S; Clements C; Samuel J; Shelmani G; Jayne S; Dyer MJ; Macip S
    Br J Haematol; 2016 Nov; 175(4):641-651. PubMed ID: 27469405
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dinaciclib potently suppresses MCL-1 and selectively induces the cell death in human iPS cells without affecting the viability of cardiac tissue.
    Alsayegh K; Matsuura K; Sekine H; Shimizu T
    Sci Rep; 2017 Mar; 7():45577. PubMed ID: 28361959
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CDK1/2/5 inhibition overcomes IFNG-mediated adaptive immune resistance in pancreatic cancer.
    Huang J; Chen P; Liu K; Liu J; Zhou B; Wu R; Peng Q; Liu ZX; Li C; Kroemer G; Lotze M; Zeh H; Kang R; Tang D
    Gut; 2021 May; 70(5):890-899. PubMed ID: 32816920
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cyclin-dependent kinase inhibitor dinaciclib potently synergizes with cisplatin in preclinical models of ovarian cancer.
    Chen XX; Xie FF; Zhu XJ; Lin F; Pan SS; Gong LH; Qiu JG; Zhang WJ; Jiang QW; Mei XL; Xue YQ; Qin WM; Shi Z; Yan XJ
    Oncotarget; 2015 Jun; 6(17):14926-39. PubMed ID: 25962959
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The CDK Inhibitor Dinaciclib Improves Cisplatin Response in Nonseminomatous Testicular Cancer: A Preclinical Study.
    Rossini E; Tamburello M; Abate A; Zini S; Ribaudo G; Gianoncelli A; Calza S; Valcamonico F; Suardi NR; Mirabella G; Berruti A; Sigala S
    Cells; 2024 Feb; 13(5):. PubMed ID: 38474332
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CDK5 inhibition in vitro and in vivo induces cell death in myeloma and overcomes the obstacle of bortezomib resistance.
    Tang H; Xu L; Cen X; Yang L; Feng J; Li G; Zhu H; Gao S; Yu Y; Zhao Y; Tian Z; Hou L; Yu S; Gao G
    Int J Mol Med; 2020 Jun; 45(6):1661-1672. PubMed ID: 32236619
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibitory Response to CK II Inhibitor Silmitasertib and CDKs Inhibitor Dinaciclib Is Related to Genetic Differences in Pancreatic Ductal Adenocarcinoma Cell Lines.
    Ma Y; Sender S; Sekora A; Kong W; Bauer P; Ameziane N; Krake S; Radefeldt M; Al-Ali R; Weiss FU; Lerch MM; Parveen A; Zechner D; Junghanss C; Murua Escobar H
    Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457227
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma.
    Kumar SK; LaPlant B; Chng WJ; Zonder J; Callander N; Fonseca R; Fruth B; Roy V; Erlichman C; Stewart AK;
    Blood; 2015 Jan; 125(3):443-8. PubMed ID: 25395429
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The CDK9 Inhibitor Dinaciclib Exerts Potent Apoptotic and Antitumor Effects in Preclinical Models of MLL-Rearranged Acute Myeloid Leukemia.
    Baker A; Gregory GP; Verbrugge I; Kats L; Hilton JJ; Vidacs E; Lee EM; Lock RB; Zuber J; Shortt J; Johnstone RW
    Cancer Res; 2016 Mar; 76(5):1158-69. PubMed ID: 26627013
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multiple CDK inhibitor dinaciclib suppresses neuroblastoma growth via inhibiting CDK2 and CDK9 activity.
    Chen Z; Wang Z; Pang JC; Yu Y; Bieerkehazhi S; Lu J; Hu T; Zhao Y; Xu X; Zhang H; Yi JS; Liu S; Yang J
    Sci Rep; 2016 Jul; 6():29090. PubMed ID: 27378523
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Maritoclax and dinaciclib inhibit MCL-1 activity and induce apoptosis in both a MCL-1-dependent and -independent manner.
    Varadarajan S; Poornima P; Milani M; Gowda K; Amin S; Wang HG; Cohen GM
    Oncotarget; 2015 May; 6(14):12668-81. PubMed ID: 26059440
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Significance of Targeting VEGFR-2 and Cyclin D1 in Luminal-A Breast Cancer.
    Abdalla AN; Qattan A; Malki WH; Shahid I; Hossain MA; Ahmed M
    Molecules; 2020 Oct; 25(20):. PubMed ID: 33050377
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dinaciclib, a Cyclin-Dependent Kinase Inhibitor Promotes Proteasomal Degradation of Mcl-1 and Enhances ABT-737-Mediated Cell Death in Malignant Human Glioma Cell Lines.
    Jane EP; Premkumar DR; Cavaleri JM; Sutera PA; Rajasekar T; Pollack IF
    J Pharmacol Exp Ther; 2016 Feb; 356(2):354-65. PubMed ID: 26585571
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dinaciclib inhibits the stemness of two subtypes of human breast cancer cells by targeting the FoxM1 and Hedgehog signaling pathway.
    Tsao AN; Chuang YS; Lin YC; Su Y; Chao TC
    Oncol Rep; 2022 May; 47(5):. PubMed ID: 35417031
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inhibition of CD73 using folate targeted nanoparticles carrying anti-CD73 siRNA potentiates anticancer efficacy of Dinaciclib.
    Hallaj S; Heydarzadeh Asl S; Alian F; Farshid S; Eshaghi FS; Namdar A; Atyabi F; Masjedi A; Hallaj T; Ghorbani A; Ghalamfarsa G; Sojoodi M; Jadidi-Niaragh F
    Life Sci; 2020 Oct; 259():118150. PubMed ID: 32726663
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phosphorylation-Induced Ubiquitination and Degradation of PXR through CDK2-TRIM21 Axis.
    Qin M; Xin Y; Bian Y; Yang X; Xi T; Xiong J
    Cells; 2022 Jan; 11(2):. PubMed ID: 35053380
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase 1 safety, pharmacokinetic and pharmacodynamic study of the cyclin-dependent kinase inhibitor dinaciclib administered every three weeks in patients with advanced malignancies.
    Mita MM; Mita AC; Moseley JL; Poon J; Small KA; Jou YM; Kirschmeier P; Zhang D; Zhu Y; Statkevich P; Sankhala KK; Sarantopoulos J; Cleary JM; Chirieac LR; Rodig SJ; Bannerji R; Shapiro GI
    Br J Cancer; 2017 Oct; 117(9):1258-1268. PubMed ID: 28859059
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cyclin-Dependent Kinase Inhibitors as Anticancer Therapeutics.
    Law ME; Corsino PE; Narayan S; Law BK
    Mol Pharmacol; 2015 Nov; 88(5):846-52. PubMed ID: 26018905
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting cyclin-dependent kinase 9 sensitizes medulloblastoma cells to chemotherapy.
    Song H; Bhakat R; Kling MJ; Coulter DW; Chaturvedi NK; Ray S; Joshi SS
    Biochem Biophys Res Commun; 2019 Dec; 520(2):250-256. PubMed ID: 31594641
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.